Despite available pharmacological treatment methods, about 25-40% of patients suffer from pharmacoresistant epilepsy. Such patients are candidates for surgery, that is, classic resectable or minimally invasive neurosurgical treatment. Vagal nerve stimulator (VNS) as minimally invasive neurosurgical treatment is indicated for the adjuvant and palliative treatment of pharmacoresistant epilepsy [1]. The side effects of VNS are mostly transient and mild, such as paraesthesia, cough, dyspnoea, pharyngitis, hoarseness, alteration of voice, neck pain, and swallowing disorders, while laryngeal muscle spasm and obstruction of upper airways occur less frequently, as well as worsening of sleep apnoea. Bradycardia, atrioventricular block, and asystole, as the most severe side effects, are very rare [2]. In 2005 VNS was approved for the adjunctive long-term treatment of chronic or recurrent depression in adult patients experiencing a major depressive episode who had failed to respond to four or more adequate antidepressant treatments. However, the efficacy of VNS for treating depression remains unclear [3].

Vogt-Koyanagi-Harada syndrome is an autoimmune, multisystem disease and important cause of uveitis. In this case report we address the significance of reliable diagnostics and including autoimmune diseases in differential diagnosis of uveitis and meningitis syndrome.